TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38885033

Group type: EXPERIMENTAL
Intervention: Digital mental health monitoring platform with wearable sensor (Fitbit Sense)
Number of subjects: 25
Study: 38885066

Group type: EXPERIMENTAL
Intervention: Dual-task training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Single-task training
Number of subjects: 44
Study: 38885086

Group type: EXPERIMENTAL
Intervention: 1L ibrutinib
Number of subjects: 0
Study: 38885234

Group type: EXPERIMENTAL
Intervention: Glenzocimab (1000 mg/day for 3 days)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Glenzocimab
Number of subjects: 61
Study: 38885246

Group type: EXPERIMENTAL
Intervention: Rucaparib 600 mg by mouth twice daily
Number of subjects: 12
Study: 38885309

Group type: EXPERIMENTAL
Intervention: S-ICD models A209 and A219
Number of subjects: 1112
Study: 38885397

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the foot (posterior tibial nerve, flexor hallucis brevis muscle)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electromyographic (EMG) monitoring at the hand (ulnar nerve, adductor pollicis muscle)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the foot
Number of subjects: 50

Group type: COMPARATOR
Intervention: Electromyographic (EMG) monitoring at the hand
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Electromyographic (EMG) monitoring at the hand and foot
Number of subjects: 50
Study: 38885481

Group type: EXPERIMENTAL
Intervention: BAFF-R CAR T-cell therapy
Number of subjects: 1

Group type: COMPARATOR
Intervention: CD19 CAR T-cell therapy
Number of subjects: 1
Study: 38885482

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CTLs (1 of 4 escalating doses, containing 68.5% SARS-CoV-2-specific CD8+ CTLs/total cells)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: SARS-CoV-2-specific CTLs
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard of care (observational group)
Number of subjects: 30
Study: 38885598

Group type: EXPERIMENTAL
Intervention: IG1 (8 biweekly social support sessions)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: IG2 (6 biweekly social support sessions)
Number of subjects: 121

Group type: COMPARATOR
Intervention: CG1 (standard care)
Number of subjects: 121

Group type: COMPARATOR
Intervention: CG2 (standard care)
Number of subjects: 121
Study: 38885672

Group type: EXPERIMENTAL
Intervention: Sovleplenib (300 mg once daily for 24 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Sovleplenib
Number of subjects: 188
Study: 38885746

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 180

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 180
Study: 38885985

Group type: EXPERIMENTAL
Intervention: Substance Use (SU)
Number of subjects: 17585

Group type: EXPERIMENTAL
Intervention: Hazardous Drinking (HD)
Number of subjects: 17585

Group type: EXPERIMENTAL
Intervention: Concurrent Substance Use and Hazardous Drinking (SU and HD)
Number of subjects: 17585

Group type: COMPARATOR
Intervention: Control group (not engaging in HD or SU)
Number of subjects: 17585
Study: 38885990

Group type: EXPERIMENTAL
Intervention: qER software by Qure.ai
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care (pre-implementation phase)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: qER solution with prioritised flag in the radiology information system (post-implementation phase)
Number of subjects: 0
Study: 38885991

Group type: EXPERIMENTAL
Intervention: Q3 (PNI ≥ 59.80)
Number of subjects: 14883

Group type: COMPARATOR
Intervention: Q2 (51.35 ≤ PNI < 59.80)
Number of subjects: 14883

Group type: EXPERIMENTAL
Intervention: Q1 (PNI <51.35)
Number of subjects: 14883
Study: 38886011

Group type: EXPERIMENTAL
Intervention: Lateral episiotomy
Number of subjects: 717

Group type: COMPARATOR
Intervention: No episiotomy
Number of subjects: 717

Group type: COMPARATOR
Intervention: No significant differences
Number of subjects: 717
Study: 38886116

Group type: EXPERIMENTAL
Intervention: AdAPT-001
Number of subjects: 0
Study: 38886159

Group type: EXPERIMENTAL
Intervention: Entinostat 5 mg weekly
Number of subjects: 5
Study: 38886235

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided preemptive retrolaminar block (RLB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 60
Study: 38886304

Group type: EXPERIMENTAL
Intervention: 6-minute walk test
Number of subjects: 22

Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test (VO2)
Number of subjects: 22
Study: 38886347

Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at recommended phase 2 dose (RP2D) of 2.3 mg/kg once every 3 weeks.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at doses of 3.0 and 3.5 mg/kg.
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: FS-1502 (anti-HER2 ADC) at RP2D of 2.3 mg/kg.
Number of subjects: 150
Study: 38886516

Group type: EXPERIMENTAL
Intervention: Talazoparib
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 2
Study: 38886623

Group type: EXPERIMENTAL
Intervention: Duvelisib plus romidepsin
Number of subjects: 98

Group type: COMPARATOR
Intervention: Duvelisib plus bortezomib
Number of subjects: 98
Study: 38886719

Group type: EXPERIMENTAL
Intervention: Qualitative strategies for quitting vaping
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Barriers to quitting vaping
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Quit strategies for vaping
Number of subjects: 11
Study: 38886774

Group type: EXPERIMENTAL
Intervention: Distance-dependent functional connectivity density (FCD) in left subcortical stroke patients (LSS)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Distance-dependent functional connectivity density (FCD) in right subcortical stroke patients (RSS)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 86
Study: 38886814

Group type: EXPERIMENTAL
Intervention: 6-week group-based telemedicine self-management intervention
Number of subjects: 50

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 50
Study: 38886836

Group type: EXPERIMENTAL
Intervention: Bevacizumab-based chemotherapy
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TTLD ratio > 0.6 at baseline and first restaging
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline TTLD ratio > 0.6
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: TTLD absolute values at baseline and first restaging
Number of subjects: 79
Study: 38886974

Group type: EXPERIMENTAL
Intervention: Individual 'I-for-me' PA planning intervention
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Collaborative 'we-for-us' PA planning intervention
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Dyadic 'we-for-me' PA planning intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 247
Study: 38887480

Group type: EXPERIMENTAL
Intervention: HIV self-testing
Number of subjects: 40
Study: 38887493

Group type: EXPERIMENTAL
Intervention: Gut microbiota and metabolites analysis in SA-AKI patients
Number of subjects: 4

Group type: COMPARATOR
Intervention: Gut microbiota and metabolites analysis in non-AKI patients
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Comparative analysis of gut microbiota and metabolites
Number of subjects: 4
Study: 38887884

Group type: EXPERIMENTAL
Intervention: Selective intracoronary hypothermia during primary PCI
Number of subjects: 200

Group type: COMPARATOR
Intervention: Primary PCI alone
Number of subjects: 200
Study: 38887951

Group type: EXPERIMENTAL
Intervention: Physiology-guided complete revascularization
Number of subjects: 1445

Group type: COMPARATOR
Intervention: Culprit-only revascularization
Number of subjects: 1445
Study: 38887953

Group type: EXPERIMENTAL
Intervention: Text messages encouraging low-level physical activity (delivered via smartwatch)
Number of subjects: 108

Group type: COMPARATOR
Intervention: No text message (control group)
Number of subjects: 108
Study: 38888179

Group type: EXPERIMENTAL
Intervention: GLP-2 + CCK (10 pmol × kg-1 × min-1 + 0.4 pmol × kg-1 × min-1)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: GLP-2 + placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: CCK + placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: placebo + placebo
Number of subjects: 15
Study: 38888288

Group type: EXPERIMENTAL
Intervention: Voretigene neparvovec-rzyl
Number of subjects: 4

Group type: COMPARATOR
Intervention: rAAV2-CB-hRPE65
Number of subjects: 4
Study: 38888480

Group type: EXPERIMENTAL
Intervention: FFDM plus UST
Number of subjects: 140

Group type: COMPARATOR
Intervention: FFDM alone
Number of subjects: 140
Study: 38888484

Group type: EXPERIMENTAL
Intervention: Affibody-based tracer (specific details not provided)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspecific radiotracers (specific details not provided)
Number of subjects: 0
Study: 38888538

Group type: EXPERIMENTAL
Intervention: PortionSize
Number of subjects: 14
Study: 38888616

Group type: EXPERIMENTAL
Intervention: zanubrutinib (160 mg twice-daily)
Number of subjects: 90

Group type: COMPARATOR
Intervention: ibrutinib (420 mg once-daily)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: zanubrutinib
Number of subjects: 90

Group type: COMPARATOR
Intervention: ibrutinib
Number of subjects: 90
Study: 38888681

Group type: EXPERIMENTAL
Intervention: Abrocitinib 200 mg
Number of subjects: 3802

Group type: EXPERIMENTAL
Intervention: Abrocitinib 100 mg
Number of subjects: 3802

Group type: COMPARATOR
Intervention: Abrocitinib (variable-dose cohort)
Number of subjects: 3802

Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 3802
Study: 38888700

Group type: EXPERIMENTAL
Intervention: Tobacco heating system (THS) smokers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cigarette smokers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 0
Study: 38888846

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (0.9% saline)
Number of subjects: 0
Study: 38888905

Group type: EXPERIMENTAL
Intervention: Nonphysician community health care practitioner-led intensive blood pressure intervention
Number of subjects: 22386

Group type: COMPARATOR
Intervention: Usual-care group
Number of subjects: 22386
Study: 38888909

Group type: EXPERIMENTAL
Intervention: Novel highly sensitive immunoassay for long cTnT using upconversion luminescence
Number of subjects: 67

Group type: COMPARATOR
Intervention: Previously developed TRF long cTnT assay
Number of subjects: 67

Group type: COMPARATOR
Intervention: Commercial high-sensitivity cTnT assay
Number of subjects: 67
Study: 38888952

Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) for screening neurodevelopmental disorders (NDDs) and preventing postnatal depression (PND)
Number of subjects: 55618

Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) for PND detection
Number of subjects: 55618

Group type: EXPERIMENTAL
Intervention: Mobile health app (Malo) user satisfaction
Number of subjects: 55618
Study: 38888958

Group type: EXPERIMENTAL
Intervention: 8-week MBCT intervention plus treatment as usual (MBCT + TAU)
Number of subjects: 128

Group type: COMPARATOR
Intervention: 8-week waitlist control group
Number of subjects: 128
Study: 38889140

Group type: EXPERIMENTAL
Intervention: CPAP + standard physiotherapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: BiPAP + standard physiotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: standard physiotherapy
Number of subjects: 63
Study: 38889160

Group type: EXPERIMENTAL
Intervention: Outpatient treatment for psychotic disorders
Number of subjects: 66
Study: 38889213

Group type: EXPERIMENTAL
Intervention: CMR-QP (Cardiac Magnetic Resonance Quantitative Perfusion) interpretation by an expert reader
Number of subjects: 359

Group type: COMPARATOR
Intervention: Visual analysis alone
Number of subjects: 359

Group type: EXPERIMENTAL
Intervention: CMR-QP
Number of subjects: 359
Study: 38889247

Group type: EXPERIMENTAL
Intervention: mRNA-1345 50-µg vaccine
Number of subjects: 17793

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17793
Study: 38889372

Group type: EXPERIMENTAL
Intervention: European Organisation for Research and Treatment of Cancer QoL Core 30 questionnaire (QLQ-C30) summary score at diagnosis and 1 and 2 years postdiagnosis.
Number of subjects: 5915

Group type: EXPERIMENTAL
Intervention: Regression-based slope index of inequality (SII) for QLQ-C30 summary score.
Number of subjects: 5915
Study: 38889373

Group type: EXPERIMENTAL
Intervention: Amcenestrant 200 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Number of subjects: 1068

Group type: COMPARATOR
Intervention: Letrozole 2.5 mg once daily + palbociclib 125 mg once daily (21 days on/7 days off)
Number of subjects: 1068
Study: 38889377

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 1197

Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy
Number of subjects: 1197
Study: 38889431

Group type: EXPERIMENTAL
Intervention: Topical sildenafil cream (3.6%)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 200
Study: 38889737

Group type: EXPERIMENTAL
Intervention: Epcoritamab monotherapy
Number of subjects: 128
Study: 38889735

Group type: EXPERIMENTAL
Intervention: D-VTd (bortezomib, thalidomide, and dexamethasone with daratumumab)
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: D-VTd with daratumumab maintenance
Number of subjects: 1085

Group type: EXPERIMENTAL
Intervention: VTd with daratumumab maintenance
Number of subjects: 1085

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 1085
Study: 38889946

Group type: EXPERIMENTAL
Intervention: Flow cytometric analysis of peripheral blood neutrophil myeloperoxidase expression
Number of subjects: 400

Group type: COMPARATOR
Intervention: Reference standard (cytomorphological evaluation of bone marrow)
Number of subjects: 400
Study: 38890129

Group type: EXPERIMENTAL
Intervention: Cobalt-chromium thin-strut polymer-free biolimus-coated stent (CoCr-BCS)
Number of subjects: 57
Study: 38890164

Group type: EXPERIMENTAL
Intervention: HFNO and non-invasive mechanical ventilation
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pulmonary co-infection
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Invasive mechanical ventilation
Number of subjects: 107

Group type: COMPARATOR
Intervention: Standard oxygen therapy
Number of subjects: 107

Group type: COMPARATOR
Intervention: Overall management
Number of subjects: 107
Study: 38890182

Group type: EXPERIMENTAL
Intervention: Patient-selected music
Number of subjects: 321

Group type: COMPARATOR
Intervention: Silence
Number of subjects: 321
Study: 38890186

Group type: EXPERIMENTAL
Intervention: Low-level light/laser therapy (LLLT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fractional carbon dioxide laser (FCO2)
Number of subjects: 0
Study: 38890239

Group type: EXPERIMENTAL
Intervention: TEAS plus remimazolam (group E)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Fentanyl plus remimazolam (group C)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Placebo-TEAS plus remimazolam (group P)
Number of subjects: 108
Study: 38890271

Group type: EXPERIMENTAL
Intervention: Pf-infected mosquitoes exposure
Number of subjects: 8
Study: 38890302

Group type: EXPERIMENTAL
Intervention: Rice fortified with vitamins and minerals (specific types not detailed) for six months
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 380
Study: 38890563

Group type: EXPERIMENTAL
Intervention: MaxiPost (0.05 mg/min)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 21
Study: 38890627

Group type: EXPERIMENTAL
Intervention: Nano Silver Fluoride (NSF)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Silver Diamine Fluoride (SDF)
Number of subjects: 360
Study: 38890641

Group type: EXPERIMENTAL
Intervention: eliapixant 25 mg BID
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: eliapixant 75 mg BID
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: eliapixant 150 mg BID
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: elagolix 150 mg once daily
Number of subjects: 215
Study: 38890655

Group type: EXPERIMENTAL
Intervention: IV-DXN (4 mg/ml DXN)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PN-DXN (1 ml of 4 mg/ml DXN)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (saline)
Number of subjects: 45
Study: 38890709

Group type: EXPERIMENTAL
Intervention: Online self-help 14-day Acceptance and Commitment Therapy (ACT) training
Number of subjects: 192

Group type: COMPARATOR
Intervention: Minimally enhanced usual care (mEUC) control group
Number of subjects: 192
Study: 38890744

Group type: EXPERIMENTAL
Intervention: Unsupported pharmacy-delivered PrEP services
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Supported pharmacy-delivered PrEP services with nurse navigator
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 1900

Group type: EXPERIMENTAL
Intervention: Exploratory outcomes
Number of subjects: 1900
Study: 38891149

Group type: EXPERIMENTAL
Intervention: Manual Therapy (MT)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synchronized Telerehabilitation (TR)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Home Exercise (HE)
Number of subjects: 60
Study: 38891190

Group type: EXPERIMENTAL
Intervention: Family Club Denmark (FCD) intervention
Number of subjects: 510

Group type: COMPARATOR
Intervention: Control group (waiting list)
Number of subjects: 510
Study: 38891799

Group type: EXPERIMENTAL
Intervention: Probiotic therapy for 12 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 38892218

Group type: EXPERIMENTAL
Intervention: Plasma trimethylamine-N-oxide (TMAO) levels in LTRs
Number of subjects: 367

Group type: COMPARATOR
Intervention: Plasma trimethylamine-N-oxide (TMAO) levels in the general population (PREVEND cohort)
Number of subjects: 367
Study: 38892507

Group type: EXPERIMENTAL
Intervention: Micellar Vitamin D
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Vitamin D
Number of subjects: 0
Study: 38892525

Group type: EXPERIMENTAL
Intervention: Mediterranean low-FODMAP diet (MED-LFD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: NICE recommendations diet
Number of subjects: 0
Study: 38892738

Group type: EXPERIMENTAL
Intervention: Greater Occipital Nerve Blockade
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sphenopalatine Ganglion Blockade
Number of subjects: 0
Study: 38892841

Group type: EXPERIMENTAL
Intervention: Customized seating system with hips significantly abducted for at least five hours/day for two years
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adaptive seating system with pelvis and lower limbs aligned but hips less abducted
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 38892879

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38893184

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) boost, single dose of 20 Gy, administered immediately after tumor resection.
Number of subjects: 1133
Study: 38895199

Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidine treatment
Number of subjects: 0
Study: 38895600

Group type: EXPERIMENTAL
Intervention: SPAIRE approach
Number of subjects: 244

Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 244
Study: 38895640

Group type: EXPERIMENTAL
Intervention: Vibration-controlled transient elastography (VCTE) with CAP of 281 dB/m
Number of subjects: 82

Group type: COMPARATOR
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 82
Study: 38895699

Group type: EXPERIMENTAL
Intervention: Multimodal CT (NCCT, CTA, CTP)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Blinded results from imaging scans by radiologists and AI technology
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Economic indicators and costs analysis
Number of subjects: 3000
Study: 38895897

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - brief (4 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - standard (8 weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (MBI) - extended (12 weeks)
Number of subjects: 60
Study: 38896056

Group type: EXPERIMENTAL
Intervention: NPM1 testing
Number of subjects: 7285

Group type: EXPERIMENTAL
Intervention: FLT3-ITD testing
Number of subjects: 7285

Group type: EXPERIMENTAL
Intervention: NGS testing
Number of subjects: 7285

Group type: EXPERIMENTAL
Intervention: Karyotype studies
Number of subjects: 7285

Group type: EXPERIMENTAL
Intervention: Fluorescence in situ hybridization studies
Number of subjects: 7285

Group type: EXPERIMENTAL
Intervention: Performing genetic studies
Number of subjects: 7285
Study: 38896141

Group type: EXPERIMENTAL
Intervention: fSCIG 10% with conventional ramp-up at 1.0 g/kg/infusion
Number of subjects: 51

Group type: COMPARATOR
Intervention: fSCIG 10% with no ramp-up at 1.0 g/kg/infusion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: fSCIG 10% with accelerated ramp-up at 1.0 g/kg/infusion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: fSCIG 10% with conventional ramp-up at 0.4 g/kg/infusion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: fSCIG 10% (all arms)
Number of subjects: 51
Study: 38896199

Group type: EXPERIMENTAL
Intervention: Mirogabalin 15 mg twice daily (after uptitration from 5 mg twice daily for the first week)
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: Mirogabalin
Number of subjects: 393

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 393
Study: 38896211

Group type: EXPERIMENTAL
Intervention: Cognitive training (CT) program (30 sessions, 90 min each)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control group (routine activities)
Number of subjects: 226
Study: 38896223

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LpHEAL9)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 + Berries
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Lactiplantibacillus plantarum HEAL9 (LpHEAL9) and LpHEAL9 + Berries
Number of subjects: 66
Study: 38896229

Group type: EXPERIMENTAL
Intervention: vWF-Ag
Number of subjects: 72

Group type: COMPARATOR
Intervention: Indocyanine green clearance
Number of subjects: 72

Group type: COMPARATOR
Intervention: Computation of future liver remnant
Number of subjects: 72
Study: 38896264

Group type: EXPERIMENTAL
Intervention: Alglucosidase alfa treatment for ≤13 years
Number of subjects: 485